Skip to search formSkip to main contentSkip to account menu

PF 03814735

Known as: Aurora Kinase Inhibitor PF-03814735, PF-03814735, PF03814735 
An aurora kinase inhibitor with potential antineoplastic activity. PF-03814735 binds to and inhibits aurora kinases, serine-threonine kinases that… 
National Institutes of Health

Related topics

Related topics

1 relation
Aurora Kinase A

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Toward In Vitro Epigenetic Drug Design for Thyroid Cancer: The Promise of PF-03814735, an Aurora Kinase Inhibitor.
Thyroid cancer (TC) is a very common malignancy worldwide. Chief among the innovative molecular drug targets for TC are… 
2019
2019
Characterization of in vitro metabolism of focal adhesion kinase inhibitors by LC/MS/MS
2008
2008
Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: Preliminary results
2517 Background: Aurora kinases are a family of kinases that play a crucial role in regulating segregation of chromosomes and… 
2008
2008
282 POSTER Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced…
2008
2008
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)